← All trials
NCT05170737
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 1, 2021
- Primary completion
- Jun 28, 2022
- Completion date
- Oct 30, 2022
- First posted
- Dec 28, 2021
- Last posted
- Jul 20, 2022
- Enrollment
- 68
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Aelis FarmaLead sponsor
- Fundació IMIM - Parc de Salut MarOverall official - principal investigator
- European CommissionCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.